R-Hydroxybupropion

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: R-Hydroxybupropion
• 英文别名: (2R)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one
• 化学式: C₁₃H₁₈ClNO₂
• 分子量: 255.74
• InChiKey: AKOAEVOSDHIVFX-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

ADMET

代谢

(2R)-1-(3-氯苯基)-2-[(1-羟基-2-甲基丙烷-2-基)氨基]丙烷-1-酮是已知的人类代谢物，来源于(R)-安非他酮。

(2R)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one is a known human metabolite of (r)-bupropion.

来源:NORMAN Suspect List Exchange

文献信息

• THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS
  申请人：MORGAN F. Philip

  公开号：US20070155729A1

  公开（公告）日：2007-07-05

  Therapeutic amine-arylsulfonamide conjugate compounds, of the general formula: wherein R′ is [D-W-], hydroxyl, or alkoxyl; R″ is independently [D-W′-], hydrogen, alkoxy, alkyl, cycloalkyl, alkenyl, alkynyl or aryl, or R″ and R″ together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7- or 8-membered ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur; D is independently a therapeutic amine radical comprising at least one nitrogen atom and optionally at least one oxygen atom coupled to W or W′ by a nitrogen or oxygen atom; W and W′ are a chemical bond or linker; wherein either R′ is [D-W-] or at least one R″ is [D-W′-], and pharmaceutically acceptable esters, amides, salts or solvates thereof, pharmaceutical compositions containing same, methods for their preparation, and their use in treating psychiatric, neurologic and metabolic disorders are disclosed.

  治疗性胺基芳砜酰胺共轭化合物，一般式如下： 其中R′为[D-W-]，羟基或烷氧基；R″独立为[D-W′-]，氢，烷氧基，烷基，环烷基，烯基，炔基或芳基，或R″和R″与它们连接的氮原子一起形成一个含有一个或两个进一步异原子（独立选择自氮、氧和硫）的4、5、6、7或8元环，D独立为至少含有一个氮原子和可选地至少一个氧原子的治疗性胺基基团，通过氮或氧原子与W或W′偶联；W和W′为化学键或连接物；其中R′为[D-W-]或至少一个R″为[D-W′-]，以及其药学上可接受的酯、酰胺、盐或溶剂化合物，含有相同化合物的药物组合物，其制备方法，以及它们在治疗精神病、神经病和代谢性疾病中的用途。
• Bupropion Metabolites and Methods of Their Synthesis and Use
  申请人：FANG Kevin Qun

  公开号：US20100125070A1

  公开（公告）日：2010-05-20

  Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.

  本文披露了利用伯泊隆代谢产物治疗通过抑制神经元单胺再摄取得到改善的疾病的方法和组合物。这些疾病包括但不限于性功能障碍、情感障碍、脑功能障碍、吸烟和失禁。本文还披露了制备光学纯伯泊隆代谢产物的方法。
• BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE
  申请人：SEPRACOR, INC.

  公开号：EP1259243B2

  公开（公告）日：2010-07-21
• US7763612B2
  申请人：——

  公开号：US7763612B2

  公开（公告）日：2010-07-27